Coeptis Therapeutics announces 1-for-20 reverse stock split

Coeptis Therapeutics (COEP) announced it will proceed with a 1-for-20 reverse stock split of its issued and outstanding shares of common stock, following authorization by its board of directors and majority stockholders to effect a reverse stock split by a ratio of not less than 1-for-3 and not more than 1-for-40, with the Board having the discretion as to whether or not the Reverse Split is to be effected, and the exact ratio to be set at a whole number within the Reverse Split Range. The first day of trading on a post-split basis on the Nasdaq Capital Market, will be at market open on December 31.